Format

Send to

Choose Destination
Trends Pharmacol Sci. 2009 Nov;30(11):600-7. doi: 10.1016/j.tips.2009.08.003.

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

Author information

1
School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia.

Abstract

Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4-specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non-specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.

PMID:
19837468
DOI:
10.1016/j.tips.2009.08.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center